{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:17Z","timestamp":1791876917248,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,30]],"date-time":"2027-01-30T00:00:00Z","timestamp":1801267200000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 012187"],"award-info":[{"award-number":["ZIA BC 012187"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["K12TR005104"],"award-info":[{"award-number":["K12TR005104"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2025.09.028","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:12:06Z","timestamp":1759345926000},"page":"158-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-3569","authenticated-orcid":false,"given":"Kevin O.","family":"McNerney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-3836","authenticated-orcid":false,"given":"Caroline","family":"Diorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Annesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-8906","authenticated-orcid":false,"given":"Andrea K.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7434-6747","authenticated-orcid":false,"given":"Lazaro N.","family":"Sanchez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda K.","family":"Ombrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6558-6706","authenticated-orcid":false,"given":"Aimee C.","family":"Talleur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9512-7597","authenticated-orcid":false,"given":"Liora M.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Maude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2025.09.028_bib0001","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jtct.2025.09.028_bib0002","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.028_bib0003","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.028_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.028_bib0005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Therapy"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.028_bib0007","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.028_bib0008","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.jtct.2025.09.028_bib0009","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.09.028_bib0010","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/bloodadvances.2024015161","article-title":"Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma","volume":"9","author":"Frigault","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.028_bib0011","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.jtct.2023.12.233","article-title":"Planned interim analysis of a phase 2 investigator-initiated trial of anakinra to prevent CRS and neurotoxicity after treatment with lisocabtagene maraleucel","volume":"30","author":"Liang","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.028_bib0012","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.jtct.2025.09.028_bib0013","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","article-title":"A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma","volume":"7","author":"Strati","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.09.028_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.028_bib0015","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.09.028_bib0016","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.028_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jtct.2023.10.006","article-title":"INSPIRED symposium part 3: prevention and management of pediatric chimeric antigen receptor T cell-associated emergent toxicities","volume":"30","author":"McNerney","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.09.028_bib0018","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.028_bib0019","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.jtct.2025.09.028_bib0020","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.028_bib0021","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"14","key":"10.1016\/j.jtct.2025.09.028_bib0022","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2217\/imt-2020-0116","article-title":"Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function","volume":"12","author":"Wei","year":"2020","journal-title":"Immunotherapy"},{"issue":"19","key":"10.1016\/j.jtct.2025.09.028_bib0023","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025786","article-title":"Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: a case report","volume":"100","author":"Zi","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.028_bib0024","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFNgamma inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.028_bib0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-gamma blockade in CAR T-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jtct.2025.09.028_bib0026","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3324\/haematol.2023.284784","article-title":"Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series","volume":"109","author":"Scala","year":"2024","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.jtct.2025.09.028_bib0027","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.028_bib0028","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.09.028_bib0029","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.028_bib0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.09.028_bib0031","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.028_bib0032","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.09.028_bib0033","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.028_bib0034","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/08880018.2021.1988012","article-title":"Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults","volume":"39","author":"Dreyzin","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"issue":"17","key":"10.1016\/j.jtct.2025.09.028_bib0035","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.09.028_bib0036","series-title":"IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome","author":"Oliai","year":"2021"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.028_bib0037","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.jtct.2025.09.028_bib0038","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.jtct.2025.09.028_bib0039","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2025.09.028_bib0040","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/blood-2021-146927","article-title":"A phase II trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity","volume":"138","author":"Frigault","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.09.028_bib0041","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2025.09.028_bib0042","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725014526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:22:25Z","timestamp":1773278545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725014526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666636725014526"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.028","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}